Ipsen Pharma S.A.S. v Allergan, Inc

Link copied
Case Copied 8 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Ipsen Pharma S.A.S.  v Allergan, Inc 2013 APO 50

Patent Application:                   2005200251

Title:Method for treating pain associated with a muscle disorder                   

Patent Applicant:  Allergan, Inc

Opponent:  Ipsen Pharma S.A.S.

Delegate:  Sophina Calanni

Decision Date:  29 August 2013

Hearing Date:  5 June 2013, in Canberra

Catchwords:  PATENTS – final determination of an opposition under section 59 – whether amendments overcome the deficiencies in the opposed claims – claims lack novelty – claims lack an inventive step – application refused

Representation:  Patent Applicant:  Dr Gavin Recchia and Ms Joanna Jones of Davies Collison Cave (Sydney)

Opponent: Mr Ian Horak of Counsel, instructed by Ms Amanda Jones of Watermark (Melbourne) 

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                   2005200251

Title:Method for treating pain associated with a muscle disorder

Patent Applicant:  Allergan, Inc.

Date of Decision:  29 August 2013

DECISION

Claims 1-7 lack novelty.


Claims 1-7 lack an inventive step.

I award costs against the Applicant, Allergan, Inc.

REASONS FOR DECISION

BACKGROUND

  1. Grant of a patent for application 2005200251 in the name of Allergan, Inc. was opposed by Ipsen Pharma S.A.S.. Following a hearing on 21 September 2011, a Delegate of the Commissioner issued a decision upholding the opposition on the grounds that the claims lack novelty and an inventive step (see Ipsen Pharma S.A.S. v Allergan, Inc [2012] APO 21.)

  2. The Delegate allowed the Applicant 2 months from the date of the decision to make suitable amendments to overcome the deficiencies. Amendments were proposed by the Applicant on 10 April 2012, and allowance was advertised in the Official Journal on 6 December 2012.  The opponent requested to be heard on the final determination of the opposition.

    DECISION

    The amendments

  3. Compared with the opposed claims, claims 1 and 6 were amended to incorporate the feature that the therapeutically effective amount of botulinum toxin used is 50 to 300 units.

  4. With the additional text underlined, claim 1 as amended reads:

    “1.  A method for treating post stroke spasticity pain, the method comprising the step of intramuscular injection to a cholinergic influenced muscle of a patient a therapeutically effective amount of botulinum toxin type A, thereby reducing a post stroke spasticity pain, wherein the therapeutically effective amount of botulinum toxin is from 50 to 300 units.”

  5. A similar amendment was made to claim 6.  With the additional text underlined, claim 6 as amended reads:

    “6.  Use of botulinum toxin type A for the manufacture of a medicament for the treatment of post stroke spasticity pain, wherein the medicament is administered to a cholinergic influenced muscle of a patient by intra-muscular injection, wherein the administration is of a therapeutically effective amount of the botulinum toxin type A, and wherein the therapeutically effective amount of the toxin is from 50 to 300 units.”

  6. Omnibus claim 7 was not amended. 

  7. The earlier decision is final and determined all the relevant issues that were capable of determination at the time (R v Smith; Ex parte Mole Engineering Pty Ltd [1981] HCA 25

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Ipsen Pharma S.A.S. v Allergan, Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] APO 50
Decision Date

CaseChat Overview and Summary

Ipsen Pharma S.A.S. opposed the grant of patent application 2005200251 in the name of Allergan, Inc., which claimed a method for treating pain associated with a muscle disorder. The opposition was upheld by a Delegate of the Commissioner, who found that the claims lacked both novelty and an inventive step. Allergan, Inc. was granted two months to amend the claims to overcome the deficiencies. Following a hearing, the Delegate made a final determination that the amended claims still lacked novelty and an inventive step and refused the application.

The primary legal issues were whether the proposed amendments overcame the deficiencies in the opposed claims. Specifically, the court had to determine if the claims lacked novelty and an inventive step in light of the prior art. The court also had to consider whether there was further opportunity for the applicant to amend the claims.

The court found that the amendments did not overcome the deficiencies in the claims. The court held that the introduction of a dosage range of 50 to 300 units of botulinum toxin did not confer novelty on the claimed subject matter as it was already disclosed in the prior art. Similarly, the court held that the introduction of the dosage range did not confer inventiveness on the claims. The court also found that it was not clear that the applicant could propose allowable amendments that would overcome the identified deficiencies. The court therefore made a final determination that the application was refused.

The court ordered that costs follow the event. Allergan, Inc. was ordered to pay the costs of Ipsen Pharma S.A.S. in relation to the final determination.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.